• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Teva to buy Allergan's generic business

Quote








we need growth beyond volume. Once we get on that treadmill Brent needs to get revenues somewhere. They just bought Naurex on the cheap so bravo for that. But who ever believes anything management says!
 
















anonymous said:
So all that change over the last year, and we are basically back to being Allergan. WTF? Someone put the for sale sign on our yard please.
Click to expand...

You/we aren't Allergan, it's just a name now, a name on a shell of a "company." Allergan, Forest, Actavis are all in the history books now. This is the M&A Wall Street machine, not a real company anymore.
 




So much for the US stopping inversion ... with the sell of generics Allergan has effectively inverted to Irish domain, and upgraded to a management that will leverage a balance sheet.
 




Top Bottom
Back
Quote